Comerica Bank raised its stake in Catalent Inc (NYSE:CTLT) by 2.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 105,494 shares of the company’s stock after acquiring an additional 2,382 shares during the period. Comerica Bank owned approximately 0.08% of Catalent worth $4,868,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. PNC Financial Services Group Inc. increased its stake in shares of Catalent by 111.5% in the 2nd quarter. PNC Financial Services Group Inc. now owns 12,838 shares of the company’s stock valued at $451,000 after purchasing an additional 6,768 shares during the last quarter. Advisor Group Inc. increased its stake in shares of Catalent by 1.3% in the 2nd quarter. Advisor Group Inc. now owns 5,185 shares of the company’s stock valued at $180,000 after purchasing an additional 65 shares during the last quarter. Stifel Financial Corp increased its stake in shares of Catalent by 0.9% in the 2nd quarter. Stifel Financial Corp now owns 10,694 shares of the company’s stock valued at $377,000 after purchasing an additional 96 shares during the last quarter. AHL Partners LLP bought a new position in shares of Catalent in the 2nd quarter valued at $424,000. Finally, Royal Bank of Canada increased its stake in shares of Catalent by 46.7% in the 2nd quarter. Royal Bank of Canada now owns 35,029 shares of the company’s stock valued at $1,230,000 after purchasing an additional 11,151 shares during the last quarter. 99.82% of the stock is owned by hedge funds and other institutional investors.
CTLT has been the topic of several recent analyst reports. BidaskClub lowered Catalent from a “buy” rating to a “hold” rating in a research note on Tuesday, November 14th. First Analysis initiated coverage on Catalent in a research note on Friday, January 5th. They issued an “equal weight” rating on the stock. Zacks Investment Research upgraded Catalent from a “hold” rating to a “strong-buy” rating and set a $49.00 price target on the stock in a research note on Thursday, October 26th. Stephens lowered Catalent from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, February 6th. Finally, Bank of America lifted their price target on Catalent from $47.00 to $49.00 and gave the company a “buy” rating in a research note on Tuesday, February 6th. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $45.60.
In other news, Director Uwe Roehrhoff acquired 7,500 shares of Catalent stock in a transaction that occurred on Tuesday, November 21st. The shares were acquired at an average price of $39.22 per share, for a total transaction of $294,150.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider John R. Chiminski sold 181,458 shares of the business’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $39.62, for a total value of $7,189,365.96. The disclosure for this sale can be found here. Insiders own 1.70% of the company’s stock.
Shares of Catalent Inc (NYSE:CTLT) opened at $40.81 on Wednesday. The firm has a market capitalization of $5,415.41, a price-to-earnings ratio of 25.39, a P/E/G ratio of 2.33 and a beta of 1.47. Catalent Inc has a 52-week low of $27.48 and a 52-week high of $47.87. The company has a current ratio of 2.22, a quick ratio of 1.78 and a debt-to-equity ratio of 2.66.
Catalent (NYSE:CTLT) last issued its quarterly earnings data on Monday, February 5th. The company reported $0.41 earnings per share for the quarter, topping analysts’ consensus estimates of $0.31 by $0.10. The business had revenue of $606.30 million for the quarter, compared to analyst estimates of $565.05 million. Catalent had a return on equity of 23.85% and a net margin of 3.03%. Catalent’s quarterly revenue was up 25.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.27 EPS. analysts forecast that Catalent Inc will post 1.53 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Comerica Bank Has $4.87 Million Holdings in Catalent Inc (CTLT)” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/14/comerica-bank-has-4-87-million-holdings-in-catalent-inc-ctlt.html.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.